Androgen Deprivation Therapy News and Research

RSS

Results of PCF funded study could impact the standard of care for prostate cancer patients

Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).

21 Aug 2009

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.

11 Aug 2009

Gtx, Inc. reports Q2 2009 results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2009. The net loss for the second quarter and six months ended June 30, 2009 was $11.3 million and $22.6 million, respectively, compared with a net loss of $13.2 million and $26.0 million for the same periods in 2008. At June 30, 2009 GTx had cash, cash equivalents and short-term investments of $68.9 million.

10 Aug 2009

Study finds few patients die from prostate cancer within 15 years of radical prostatectomy

Investigators at Memorial Sloan-Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.

28 Jul 2009

$Prostate cancer therapy increases risk of fractures and cardiovascular-related death$

Prostate cancer therapy increases risk of fractures and cardiovascular-related death

Prostate cancer patients who undergo therapy to decrease testosterone levels increase their risk of developing bone- and heart-related side effects compared to patients who do not take these medications, according to a new analysis.

27 Apr 2009

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.

27 Apr 2009

Breast and prostate cancer treatment may result in bone loss

A new cross-Canada study has found that breast and prostate cancer treatment can foster bone loss.

16 Nov 2008

Why hormone therapy for prostate cancer fails

Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences.

21 Aug 2008

Androgen deprivation therapy does not improve survival for elderly men with localized prostate cancer

A therapy that involves depriving the prostate gland the male hormone androgen is not associated with improved survival for elderly men with localized prostate cancer, compared to conservative management of the disease, according to a study in the July 9 issue of JAMA, the Journal of the American Medical Association.

9 Jul 2008

Prostate Cancer Foundation 'beefs up' cancer research

The Prostate Cancer Foundation (PCF) has committed more than $19 million in new research funding for scientific investigations focused on discovering new treatments for recurrent prostate cancer. A total of eight programs representing 18 leading research institutions and 36 researchers were selected as part of the foundation's 2008 Challenge Awards. The funded programs will receive the first of three annual payments, ranging between $500,000 and $1.0 million per program, this week.

4 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.

2 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

1 Jun 2008

Estrogen drives distinct, aggressive prostate cancer

Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.

28 May 2008

$Hormone refractory prostate cancers more likely to spread to other organs$

Hormone refractory prostate cancers more likely to spread to other organs

Prostate cancers that are resistant to androgen deprivation therapy are more invasive and more likely to spread to other organs than androgen dependent prostate cancers, UCLA cancer researchers have found.

21 Feb 2008

$Hormone refractory prostate cancers more likely to spread to other organs$

Hormone refractory prostate cancers more likely to spread to other organs

20 Feb 2008

Testosterone levels may affect men's cognitive performance

When we think about the powers of testosterone, we usually do not consider mental processes.

8 Jan 2008

Benefits of short-term hormonal therapy for men receiving radiation therapy for prostate cancer far outweigh the risks

Researchers report that just four months of hormonal therapy before and with standard external beam radiation therapy slowed cancer growth by as much as eight years - especially the development of bone metastases - and increased survival in older men with potentially aggressive prostate cancer.

4 Jan 2008

Testosterone therapy and mental function in healthy older men

When we think about the powers of testosterone, we usually do not consider mental processes.

3 Jan 2008

New drug target for treatment-resistant prostate cancer

Scientists at Jefferson's Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy.

2 Jan 2008

Radiation seed implant decreases risk of death over watchful waiting/active surveillance for prostate cancer

Prostate cancer patients cut their risk of dying of the disease in half when they receive radiation seed implants (brachytherapy) to treat their cancer, compared to those who don't receive active treatment (watchful waiting/active surveillance), within six months from being diagnosed with localized prostate cancer, according to a study presented October 31, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

1 Nov 2007

Androgen Deprivation Therapy News and Research

Results of PCF funded study could impact the standard of care for prostate cancer patients

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Gtx, Inc. reports Q2 2009 results

Study finds few patients die from prostate cancer within 15 years of radical prostatectomy

Prostate cancer therapy increases risk of fractures and cardiovascular-related death

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Breast and prostate cancer treatment may result in bone loss

Why hormone therapy for prostate cancer fails

Androgen deprivation therapy does not improve survival for elderly men with localized prostate cancer

Prostate Cancer Foundation 'beefs up' cancer research

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

Estrogen drives distinct, aggressive prostate cancer

Hormone refractory prostate cancers more likely to spread to other organs

Hormone refractory prostate cancers more likely to spread to other organs

Testosterone levels may affect men's cognitive performance

Benefits of short-term hormonal therapy for men receiving radiation therapy for prostate cancer far outweigh the risks

Testosterone therapy and mental function in healthy older men

New drug target for treatment-resistant prostate cancer

Radiation seed implant decreases risk of death over watchful waiting/active surveillance for prostate cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News